Search
Search Results
-
Novel targeted therapies of T cell lymphomas
T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis...
-
Single-cell T-cell receptor repertoire profiling in dogs
Spontaneous cancers in companion dogs are robust models of human disease. Tracking tumor-specific immune responses in these models requires reagents...
-
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis
CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or...
-
Long-term outcomes following CAR T cell therapy: what we know so far
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer cells. CAR T cells are now...
-
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is...
-
Ultrasound of Cutaneous Lymphomas
Primary cutaneous lymphomas (PCL) are a rare heterogeneous group of lymphoproliferative disorders arising from the skin and limited to it at...
-
Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases
With inconsistent findings, evidence has been obtained in recent years that metabolic disorders are closely associated with the development of...
-
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with generally poor prognoses, and the first-line chemotherapy of...
-
Peripheral T-cell lymphomas (PTCLs) and Natural Killer (NK)-cell neoplasms
Peripheral T-cell lymphomas (PTCLs) and Natural Killer (NK)-cell neoplasms are occasionally encountered by diagnostic hematopathologists and surgical... -
Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas
Primary cutaneous lymphomas are a rare group of diseases, with an estimated incidence of 0.5–1 case per 100,000 people per year. Primary cutaneous...
-
Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers
BackgroundChimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers, which redirect T-cells to tumor antigens, have immensely...
-
Engineered T Cells: CAR T Cell Therapy and Beyond
Purpose of ReviewThis article reviews the current data and future directions of engineered T cell therapies in non-Hodgkin lymphomas.
... -
Chimeric antigen receptor T cells march into T cell malignancies
T cell malignancies represent a diverse collection of leukemia/lymphoma conditions in humans arising from aberrant T cells. Such malignancies are...
-
Miscellaneous Rare Malignancies: Intra-abdominal Lymphomas
Gastrointestinal lymphomas are a heterogeneous group of malignant diseases originating from the lymphoid tissue of the gastrointestinal system. Most...
-
EBV-associated lymphoproliferative disease post-CAR-T cell therapy
Epstein–Barr virus (EBV)-associated lymphoproliferative diseases (EBV-LPDs) are common complications that occur after solid organ transplantation or...
-
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma
The PDCD1 -encoded immune checkpoint receptor PD-1 is a key tumor suppressor in T cells that is recurrently inactivated in T cell non-Hodgkin...
-
Cutaneous Lymphomas and Lymphocytic Infiltrates
The chapter provides a review of primary cutaneous malignant lymphoid infiltrates. The first portion of the chapter addresses the T cell lymphomas,...
-
A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
Chimeric antigen receptor T-cell immunotherapy (CAR-T) has shown remarkable efficacy in treating tumors of lymphopoietic origin. Herein, we...
-
New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders
EBV-associated lymphoproliferative disorders (LPD) include conditions of B, T, and NK cell derivation with a wide clinicopathological spectrum...
-
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
Natural killer/T-cell lymphomas (NKTCL) represent rare and aggressive lymphoid malignancies. Patients (pts) with relapsed/refractory disease after...
